Background and Objectives Time Frame
A global pharma company needed to make strategic choices to acquire their next IO targets. 8 weeks
Approach and Recommendations (Methodology) Results
SmartAnalyst adopted the following approach to accomplish the objectives:

  • Conducted secondary research to map the IO universe and pre-screened the long list of pre-clinical and clinical IO targets (208) and shortlisted 25 targets for evaluation and prioritization, based on client-specific parameters.
  • Organized an Ad Board with external experts to support the evaluation and prioritization of the shortlisted targets.
  • Evaluated shortlisted targets, of which five were prioritized as ‘high’ based on
    • Biological rationale:
      • Role in cancer biology and cancer immunity cycle
      • Prognostic significance
      • Rate of aberration
    • Scientific evidence
      • Non-trivial clinical evidence
      • In vivo evidence
    • Potential combinability of select targets with other novel IO targets
    • High level commercial considerations: Breadth of applicability across tumors, competitive intensity and time to market.
SmartAnalyst identified the five most attractive IO targets, based on biologic and scientific rationale and high-level commercial considerations and developed detailed target profiles. This helped the company to frame its strategy for acquisition of IO targets.